A new secondary prevention trial in older people with amyloid accumulation at high risk for Alzheimer's disease dementia should provide insights into whether anti-amyloid therapy can delay cognitive decline.
Reisa A Sperling, Dorene M Rentz, Keith A Johnson, Jason Karlawish, Michael Donohue, David P Salmon, and Paul Aisen.
Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Sci Transl Med. 2014 Mar 19;6(228):228fs13.
AbstractA new secondary prevention trial in older people with amyloid accumulation at high risk for Alzheimer's disease dementia should provide insights into whether anti-amyloid therapy can delay cognitive decline.